ACP发布瑞德西韦用于新冠肺炎的最终实践要点

Introduction: On March 1, 2022, in a real-time systematic review and update article published online in the "Annals of Internal Medicine", the final practical points of using remdesivir for hospitalized patients with new coronary pneumonia were introduced.

Anjum S. Kaka, MD, of the Medical College of Minnesota in Minneapolis, and colleagues updated a real-time review of the use of remdesivir in hospitalized patients with COVID-19. The authors noted that since the last update, one new randomized controlled trial (RCT) and one new subtrial were identified comparing the efficacy of remdesivir to a control group (placebo or standard care) over 10 days. Based on evidence from five randomized controlled trials, a 10-day course of remdesivir may not reduce mortality compared with a control group.

Amir Qaseem, MD, of the American College of Physicians in Philadelphia, and colleagues updated the real-time, rapid practice points for remdesivir in the treatment of COVID-19. The authors noted that remdesivir should be considered for 5 days of treatment in hospitalized patients with COVID-19 who do not require invasive ventilation or extracorporeal membrane oxygenation (ECMO). For patients requiring invasive ventilation or extracorporeal membrane oxygenation within the 5-day course, consideration should be given to extending remdesivir treatment to 10 days. Remdesivir should be avoided in hospitalized patients with COVID-19 who are already receiving invasive ventilation or extracorporeal membrane oxygenation.

"Given that surveillance was originally planned to end in December 2021 and that the three most recent updates did not result in significant changes in conclusions, the Scientific Medical Policy Committee decided to remove this topic from the live status in order to balance current priorities and available resources," Qaseem and colleagues wrote.

References:

https://www.empr.com/home/news/acp-issues-final-practice-points-for-remdesivir-use-in-covid-19/